<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7999460</article-id><article-id pub-id-type="pmid">33803165</article-id><article-id pub-id-type="doi">10.3390/ph14030243</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-14-00243</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Investigation of <italic>Commiphora myrrha</italic> (Nees) Engl. Oil and Its Main Components for Antiviral Activity</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5724-612X</contrib-id><name><surname>Madia</surname><given-names>Valentina Noemi</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00243">1</xref><xref ref-type="author-notes" rid="fn1-pharmaceuticals-14-00243">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1916-6508</contrib-id><name><surname>De Angelis</surname><given-names>Marta</given-names></name><xref ref-type="aff" rid="af2-pharmaceuticals-14-00243">2</xref><xref ref-type="author-notes" rid="fn1-pharmaceuticals-14-00243">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>De Vita</surname><given-names>Daniela</given-names></name><xref ref-type="aff" rid="af3-pharmaceuticals-14-00243">3</xref><xref rid="c1-pharmaceuticals-14-00243" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Messore</surname><given-names>Antonella</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00243">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5596-7217</contrib-id><name><surname>De Leo</surname><given-names>Alessandro</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00243">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4672-2936</contrib-id><name><surname>Ialongo</surname><given-names>Davide</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00243">1</xref></contrib><contrib contrib-type="author"><name><surname>Tudino</surname><given-names>Valeria</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00243">1</xref></contrib><contrib contrib-type="author"><name><surname>Saccoliti</surname><given-names>Francesco</given-names></name><xref ref-type="aff" rid="af4-pharmaceuticals-14-00243">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2219-6097</contrib-id><name><surname>De Chiara</surname><given-names>Giovanna</given-names></name><xref ref-type="aff" rid="af5-pharmaceuticals-14-00243">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8535-0533</contrib-id><name><surname>Garzoli</surname><given-names>Stefania</given-names></name><xref ref-type="aff" rid="af6-pharmaceuticals-14-00243">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2006-7005</contrib-id><name><surname>Scipione</surname><given-names>Luigi</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00243">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8330-4381</contrib-id><name><surname>Palamara</surname><given-names>Anna Teresa</given-names></name><xref ref-type="aff" rid="af2-pharmaceuticals-14-00243">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4279-7666</contrib-id><name><surname>Di Santo</surname><given-names>Roberto</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00243">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4427-4823</contrib-id><name><surname>Nencioni</surname><given-names>Lucia</given-names></name><xref ref-type="aff" rid="af2-pharmaceuticals-14-00243">2</xref><xref ref-type="author-notes" rid="fn1-pharmaceuticals-14-00243">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Costi</surname><given-names>Roberta</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00243">1</xref><xref ref-type="author-notes" rid="fn1-pharmaceuticals-14-00243">&#x02020;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Notarbartolo</surname><given-names>Monica</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-14-00243"><label>1</label>Istituto Pasteur-Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, &#x0201c;Sapienza&#x0201d; Universit&#x000e0; di Roma, p.le Aldo Moro 5, I-00185 Rome, Italy; <email>valentinanoemi.madia@gmail.com</email> (V.N.M.); <email>antonella.messore@uniroma1.it</email> (A.M.); <email>alessandro.deleo@uniroma1.it</email> (A.D.L.); <email>ialongo.1679357@studenti.uniroma1.it</email> (D.I.); <email>valeria.tudino@uniroma1.it</email> (V.T.); <email>luigi.scipione@uniroma1.it</email> (L.S.); <email>roberto.disanto@uniroma1.it</email> (R.D.S.); <email>roberta.costi@uniroma1.it</email> (R.C.)</aff><aff id="af2-pharmaceuticals-14-00243"><label>2</label>Laboratory Affiliated to Pasteur Italia-Fondazione Cenci Bolognetti, Department of Public Health and Infectious Diseases, &#x0201c;Sapienza&#x0201d; University of Rome, p.le Aldo Moro 5, I-00185 Rome, Italy; <email>marta.deangelis@uniroma1.it</email> (M.D.A.); <email>annateresa.palamara@uniroma1.it</email> (A.T.P.); <email>lucia.nencioni@uniroma1.it</email> (L.N.)</aff><aff id="af3-pharmaceuticals-14-00243"><label>3</label>Department of Environmental Biology, &#x0201c;Sapienza&#x0201d; University of Rome, p.le Aldo Moro 5, I-00185 Rome, Italy</aff><aff id="af4-pharmaceuticals-14-00243"><label>4</label>D3 PharmaChemistry, Italian Institute of Technology, Via Morego 30, I-16163 Genova, Italy; <email>francesco.saccoliti@iit.it</email></aff><aff id="af5-pharmaceuticals-14-00243"><label>5</label>Institute of Translational Pharmacology, National Research Council (CNR), Via del Fosso del Cavaliere 100, I-00133 Rome, Italy; <email>giovanna.dechiara@ift.cnr.it</email></aff><aff id="af6-pharmaceuticals-14-00243"><label>6</label>Department of Drug Chemistry and Technologies, Sapienza University of Rome, p.le Aldo Moro 5, I-00185 Rome, Italy; <email>stefania.garzoli@uniroma1.it</email></aff><author-notes><corresp id="c1-pharmaceuticals-14-00243"><label>*</label>Correspondence: <email>daniela.devita@uniroma1.it</email>; Tel.: +39-06-4991-2788</corresp><fn id="fn1-pharmaceuticals-14-00243"><label>&#x02020;</label><p>These authors contributed equally.</p></fn></author-notes><pub-date pub-type="epub"><day>09</day><month>3</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2021</year></pub-date><volume>14</volume><issue>3</issue><elocation-id>243</elocation-id><history><date date-type="received"><day>05</day><month>2</month><year>2021</year></date><date date-type="accepted"><day>03</day><month>3</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 by the authors.</copyright-statement><copyright-year>2021</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="pmc" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The resinous exudate produced by <italic>Commiphora myrrha</italic> (Nees) Engl. is commonly known as true myrrh and has been used since antiquity for several medicinal applications. Hundreds of metabolites have been identified in the volatile component of myrrh so far, mainly sesquiterpenes. Although several efforts have been devoted to identifying these sesquiterpenes, the phytochemical analyses have been performed by gas-chromatography/mass spectrometry (GC&#x02013;MS) where the high temperature employed can promote degradation of the components. In this work, we report the extraction of <italic>C. myrrha</italic> by supercritical CO<sub>2</sub>, an extraction method known for the mild extraction conditions that allow avoiding undesired chemical reactions during the process. In addition, the analyses of myrrh oil and of its metabolites were performed by HPLC and GC&#x02013;MS. Moreover, we evaluated the antiviral activity against influenza A virus of the myrrh extracts, that was possible to appreciate after the addition of vitamin E acetate (&#x003b1;-tocopheryl acetate) to the extract. Further, the single main bioactive components of the oil of <italic>C. myrrha</italic> commercially available were tested. Interestingly, we found that both furanodienone and curzerene affect viral replication by acting on different steps of the virus life cycle.</p></abstract><kwd-group><kwd><italic>Commiphora myrrha</italic></kwd><kwd>sesquiterpenes</kwd><kwd>myrrh oil</kwd><kwd>vitamin E acetate</kwd><kwd>supercritical CO<sub>2</sub> fluid extraction</kwd><kwd>HPLC</kwd><kwd>antiviral activity</kwd><kwd>influenza A H1N1 virus</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-14-00243"><title>1. Introduction</title><p><italic>Commiphora</italic> genus (Burseraceae) includes more than 150 species especially occurring in northeastern Africa, southern Arabia and India [<xref rid="B1-pharmaceuticals-14-00243" ref-type="bibr">1</xref>]. The species <italic>Commiphora myrrha</italic> (Nees) Engl. produces a resinous exudate known as true myrrh that has been used for centuries as an embalming ointment, wound-healing remedy and for other medicinal applications [<xref rid="B2-pharmaceuticals-14-00243" ref-type="bibr">2</xref>]. Myrrh consists of alcohol-soluble resins and volatile oil together with a gum soluble in water containing polysaccharides, proteins and long chain aliphatic derivatives. The lipophilic part of myrrh is composed of steroids, sterols and terpenes [<xref rid="B3-pharmaceuticals-14-00243" ref-type="bibr">3</xref>]. To date, hundreds of metabolites have been identified in the volatile component of myrrh, where sesquiterpenes are the major components. Notably, furanosesquiterpenes such as furanoelemanes, furanoeudesmanes, and furanogermacranes are the characteristic constituents of myrrh oil [<xref rid="B4-pharmaceuticals-14-00243" ref-type="bibr">4</xref>]. As important components of volatile oil, sesquiterpenoids possess diverse biological activities, including antibacterial, antifungal, and antiparasitic properties. It is also worthy of note that recent papers reported the in vitro and in vivo analgesic and anticancer activities [<xref rid="B5-pharmaceuticals-14-00243" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceuticals-14-00243" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceuticals-14-00243" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceuticals-14-00243" ref-type="bibr">8</xref>] of four main components of the volatile oil, namely furanodienone (<bold>1</bold>), furanoeudesma-1,3-diene (<bold>2</bold>), curzerene (<bold>3</bold>), and &#x003b2;-elemene (<bold>4</bold>) (<xref ref-type="fig" rid="pharmaceuticals-14-00243-f001">Figure 1</xref>).</p><p>Some works [<xref rid="B9-pharmaceuticals-14-00243" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceuticals-14-00243" ref-type="bibr">10</xref>] have also been devoted to the identification or characterization of these aforementioned sesquiterpenes but most of the phytochemical analyses have been performed by gas chromatography where the high temperature employed can promote degradation of the components, thus influencing the qualitative&#x02013;quantitative composition of the mixture. For instance, the rearrangement of furanodiene to curzerene during the essential oil extraction process and/or during conventional gas chromatographic analysis, in which temperatures over 200 &#x000b0;C are employed, is reported [<xref rid="B11-pharmaceuticals-14-00243" ref-type="bibr">11</xref>].</p><p>Here we describe the extraction of <italic>C. myrrha</italic> by supercritical CO<sub>2</sub>, an extraction method that is well known for its many advantages in obtaining volatile extracts or aroma substances and, more generally, to extract lipophilic compounds from a wide variety of matrices. Indeed, in addition to being non-toxic and non-flammable, the mild extraction conditions allow avoiding undesired chemical reactions during the process. This leads to shorter extraction times without decomposing compounds vulnerable to high temperatures differently from hydro- or steam-distilled oils [<xref rid="B12-pharmaceuticals-14-00243" ref-type="bibr">12</xref>]. In the present work, the analysis of myrrh oil and the quantification of its metabolites were performed by HPLC, so as to avoid high temperatures also during the analytical process. Our interest in substances endowed with antiviral activity [<xref rid="B13-pharmaceuticals-14-00243" ref-type="bibr">13</xref>] and in the field of biologically active natural products [<xref rid="B14-pharmaceuticals-14-00243" ref-type="bibr">14</xref>] prompted us to evaluate the antiviral activity against influenza A virus of both the volatile myrrh extracts and of the single sesquiterpenes furanodienone (<bold>1</bold>), furanoeudesma-1,3-diene (<bold>2</bold>), curzerene (<bold>3</bold>) and &#x003b2;-elemene (<bold>4</bold>). In particular, we tested the myrrh extracts both alone and in combination with vitamin E acetate (&#x003b1;-tocopheryl acetate) in order to reduce the cytotoxic effects of the volatile oil. We decided also to investigate the activity of curzerene, furanodienone, furanoeudesma-1,3-diene and &#x003b2;-elemene <bold>1</bold>&#x02013;<bold>4</bold>, being the main bioactive components of the volatile oil of <italic>C. myrrha</italic> [<xref rid="B2-pharmaceuticals-14-00243" ref-type="bibr">2</xref>] commercially available.</p></sec><sec sec-type="results" id="sec2-pharmaceuticals-14-00243"><title>2. Results and Discussion</title><p>To determine the amount of the major sesquiterpenoids (<bold>1</bold>&#x02013;<bold>4</bold>) in our extract, an HPLC analysis was carried out. The percentage of each sesquiterpene is reported in <xref rid="pharmaceuticals-14-00243-t001" ref-type="table">Table 1</xref>. It is possible to notice that furanoeudesma-1,3-diene is the most abundant while no furanodienone was detected in our extracts. Our results are in good agreement with those found by Marongiu et al. [<xref rid="B12-pharmaceuticals-14-00243" ref-type="bibr">12</xref>] who obtained supercritical fluid extraction (SCFE) myrrh oil made up of the following main components: furanoeudesma-1,3-diene (26.2%), curzerene (9.7%), and &#x003b2;-elemene (3.0%) without detecting any amount of furanodienone. A run at low temperature was used for the HPLC analysis to isolate compound <bold>3</bold> given that it could not be separated from other compounds in the mixture at higher temperatures.</p><p>To investigate the volatile composition of <italic>C. myrrha</italic> oil, gas-chromatography/mass spectrometry (GC/MS) technique was used. Twenty-two volatile compounds were identified representing an average of 99.9% of the oil composition and they are listed in <xref rid="pharmaceuticals-14-00243-t002" ref-type="table">Table 2</xref>. The most abundant component was furanoeudesma-1,3-dione (31.1%) followed by curzerene (23.1%), germacra-1(10),7,11-trien-15-oic acid, 8,12-epoxy-6-hydroxy-gamma-lactone (14.4%), lindestrene (11.9%) and other minor compounds.</p><p>The extract obtained by supercritical fluid extraction (SCFE) using supercritical CO<sub>2</sub> as solvent has been evaluated in vitro for its antiviral activity against influenza A Puerto Rico 8/34/H1N1 virus (PR8). First, we evaluated the eventual toxicity of compounds on the cell monolayers. Therefore, intact monolayers of A549 cells were treated with different concentrations (3&#x02013;100 &#x000b5;g/mL) of myrrh oil. DMSO was used as control. The integrity of cell monolayers was evaluated by using a vital dye (Cell Tag) of cells and revealed by In-Cell Western assay (ICW). Myrrh oil alone was toxic at the highest concentrations: the integrity of cell monolayer was damaged of about 30, 71 and 76% compared to DMSO alone at 25, 50 and 100 &#x000b5;g/mL, respectively (data not shown). Due to the low stability of myrrh oil and its components in the air-oxygen environment, we hypothesized that the cytotoxicity of myrrh could be ascribed to the decomposition of the components of this oil. Thus, we decided to add a compound endowed with antioxidant properties to the extract. To this end, &#x003b1;-tocopheryl acetate and a mixture myrrh oil (3&#x02013;100 &#x000b5;g/mL) plus &#x003b1;-tocopheryl acetate (1% <italic>w</italic>/<italic>v</italic>) were tested for their toxicity. We found that the addition of 1% vitamin E acetate to myrrh oil protected the cell monolayers starting from 50 &#x000b5;g/mL. Indeed, the percentage of relative fluorescence intensity (RFI) of Cell Tag indicated a recovery of cell integrity, reaching the same percentage of not toxic concentrations (<xref ref-type="fig" rid="pharmaceuticals-14-00243-f002">Figure 2</xref>).</p><p>Therefore, since the addition of &#x003b1;-tocopheryl acetate (1% <italic>w</italic>/<italic>v</italic>) increased the viability of cells treated with the extract, in these conditions we could appreciate the antiviral activity of the mixture myrrh oil + &#x003b1;-tocopheryl acetate compared to DMSO treated&#x02013;infected cells (control) measured by means of hemagglutination assay (HAU/mL). The mixture strongly reduced viral replication in a dose-dependent manner (see <xref rid="pharmaceuticals-14-00243-t003" ref-type="table">Table 3</xref>). The viral titer was determined by evaluating the presence of hemagglutinating activity in the supernatant of infected cells. When the cells were treated with myrrh oil alone or in combination with vitamin E (Vit. E), a decrease in viral titer expressed as HAU/mL values was measured, with no observed viral titer at concentration of 50 &#x003bc;g/mL. The Vit. E acetate alone did not interfere with viral replication: indeed, at concentrations ranging from 0.03 to 1 &#x003bc;g/mL, the values of viral titer were equal to 8 HAU/mL, as for the control (DMSO).</p><p>To confirm the antiviral activity of the mixture, cells were treated with the highest concentrations (25, 50 and 100 &#x000b5;g/mL) of myrrh oil alone, myrrh oil + Vit. E (1%) and Vit. E (1%). The expression of viral nucleoprotein (NP) was analyzed by ICW, a method that allows the evaluation of the expression of viral proteins directly on an infected monolayer [<xref rid="B15-pharmaceuticals-14-00243" ref-type="bibr">15</xref>]. As shown in <xref ref-type="fig" rid="pharmaceuticals-14-00243-f003">Figure 3</xref>, the expression of NP was significantly reduced using myrrh oil at 25 and 50 &#x000b5;g/mL in mixture with Vit. E acetate, compared to Vit. E treated&#x02013;infected cells (considered as 100%). In particular, the percentage of RFI was 89.7 &#x000b1; 3% (* <italic>p</italic> &#x0003c; 0.05 vs. Vit E), 58.3 &#x000b1; 5% (** <italic>p</italic> &#x0003c; 0.01 vs. Vit. E) and 23.4 &#x000b1; 5% (** <italic>p</italic> &#x0003c; 0.01 vs. Vit. E) at 25, 50 and 100 &#x000b5;g/mL, respectively.</p><p>To further investigate the antiviral activity of myrrh oil components, we decided to test also furanodienone (<bold>1</bold>), furanoeudesma-1,3-diene (<bold>2</bold>), curzerene (<bold>3</bold>), and &#x003b2;-elemene (<bold>4</bold>) on A549 cells infected with PR8 virus. Indeed, these secondary metabolites are reported to be the main bioactive components of <italic>C. myrrha</italic> oil commercially available.</p><p>All the compounds were first tested for their potential toxicity on cell monolayer at different concentrations: furanodienone (<bold>1</bold>), curzerene (<bold>3</bold>) and &#x003b2;-elemene (<bold>4</bold>) at a range of 30&#x02013;500 &#x000b5;g/mL; furanoeudesma-1,3-diene (<bold>2</bold>) at 2.5&#x02013;30 &#x000b5;g/mL (due to the availability of a low amount of the standard compound). We found that compounds <bold>1</bold> and <bold>3</bold> showed toxicity at higher doses (starting from 100 &#x000b5;g/mL), while compound <bold>4</bold> was highly toxic at all the concentrations used. For this reason, the latter compound was excluded for the following experiments.</p><p>Compounds were added at different concentrations (30, 60 and 100 &#x000b5;g/mL) after the infection and maintained for the following 24 h. Viral replication was measured by means of HAU/mL. As shown in <xref rid="pharmaceuticals-14-00243-t004" ref-type="table">Table 4</xref>, compounds furanodienone (<bold>1</bold>) and curzerene (<bold>3</bold>) were effective at 60 and 100 &#x000b5;g/mL, even though the latter concentration was quite toxic for both compounds. In particular, for compound <bold>1</bold>, the viral titer was of 6 and 2 HAU/mL, at 60 and 100 &#x000b5;g/mL, respectively; for compound <bold>3</bold>, the viral titer was of 3 at 60 &#x000b5;g/mL, while no viral titer was observed at a concentration of 100 &#x000b5;g/mL. With regard to <bold>2</bold>, no inhibition was observed at any concentrations used (data not shown).</p><p>Thus, the antiviral activity of the effective compounds <bold>1</bold> and <bold>3</bold> was analyzed by measuring the RFI of HA protein by ICW assay. However, the highest concentration of 100 &#x000b5;g/mL was quite toxic for both compounds, therefore, we chose a lower concentration to exclude that the antiviral activity may be in part due to the cytotoxicity of compounds. Therefore, to deepen the mechanism of action of furanodienone (<bold>1</bold>) and curzerene (<bold>3</bold>)<bold>,</bold> 80 &#x000b5;g/mL was added to cells at different steps of infection: only before infection (2 h, PRE), only during infection (1 h, DUR), immediately after infection and maintained for the following 24 h (POST). Compounds were also maintained for all the time of infection (before, during and after) but in this condition, they both became toxic for the cells, and data were not considered valid. As shown in <xref ref-type="fig" rid="pharmaceuticals-14-00243-f004">Figure 4</xref>, both compounds were effective at specific phases: compound <bold>1</bold> was mainly effective when added PRE or POST (** <italic>p</italic> &#x0003c; 0.001); for compound <bold>3,</bold> although quite effective at all the phases, the most inhibition (46% compared to untreated cells) was reached during viral challenge (DUR). On the basis of these results, we hypothesize that compound <bold>1</bold> might act before infection by interfering with some cell factors on the plasma membrane or, due to the antioxidant activity of furanodienone [<xref rid="B16-pharmaceuticals-14-00243" ref-type="bibr">16</xref>], it may maintain reduced conditions into the cells making them more resistant to virus infection [<xref rid="B17-pharmaceuticals-14-00243" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceuticals-14-00243" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceuticals-14-00243" ref-type="bibr">19</xref>]. With regard to compound <bold>3</bold>, since it mainly acts during viral adsorption, it might interfere with the viral attachment or entry into the cells.</p></sec><sec id="sec3-pharmaceuticals-14-00243"><title>3. Materials and Methods</title><sec id="sec3dot1-pharmaceuticals-14-00243"><title>3.1. Materials</title><p>Oleo-gum-resin of <italic>C. mhyrra</italic> (origin Somalia) was purchased by Farmalabor (Italy). Before utilization, the material was ground with a Malavasi mill (Pinerolo, Italy) while care was taken to avoid overheating. The particles size was in the range 250&#x02013;850 &#x003bc;m. CO<sub>2</sub> (purity 99%) was supplied by SIO (Societa Italiana Ossigeno, Cagliari, Italy). Certified references furanoeudesma-1,3-diene and vitamin E acetate were purchased from Sigma-Aldrich (Milan, Italy), &#x003b2;-elemene, furanodienone and curzerene were purchased from Angene Chemicals (Nanjing, China). Acetonitrile HPLC grade was purchased from Sigma-Aldrich (Milan, Italy), and used without further purification. Water was purified before use by a Milli-Q plus 185 system (Milford, MA, USA).</p></sec><sec id="sec3dot2-pharmaceuticals-14-00243"><title>3.2. Extraction</title><p>The powdered vegetable matter (1.30 kg) underwent the extraction process with an industrial-scale supercritical fluid extraction system SCFE-10 (Exenia Group, Pinerolo, TO, Italy). The supercritical CO<sub>2</sub> extractions were performed as previously reported [<xref rid="B20-pharmaceuticals-14-00243" ref-type="bibr">20</xref>]. Briefly, in an apparatus equipped with 4200 mL extraction basket (with an internal diameter of 10 cm and an effective height of 42 cm) about 1.30 kg of myrrh was loaded at each run. Two filters of 80 &#x003bc;m were placed at both ends of the extraction basket and then placed in the 5 kg extractor vessel. The extraction parameters were set up as follows: temperature 65 &#x000b0;C, pressure 37 MPa and CO<sub>2</sub> flow rate 18 kg CO<sub>2</sub>/h. The oil was collected in a glass container, previously autoclaved and weighted. An amount of 1.30 kg of powdered myrrh yielded 45.5 g of a brown oily extract at temperature 65 &#x000b0;C, pressure 37 MPa and CO<sub>2</sub> flow rate 18 kg CO<sub>2</sub>/h.</p></sec><sec id="sec3dot3-pharmaceuticals-14-00243"><title>3.3. Analysis</title><p>Method development for analysis of the extract was carried out with an HPLC system consisting of a Shimadzu LC-10AD pump, a SIL-10AD autosampler using a 200 &#x003bc;L sample loop, a CTO-10AC column oven, a SPD-10A detector. Data analyses were performed using the LC solutions software. The HPLC analyses were performed using an analytical column Waters Symmetry C18 (150 mm &#x000d7; 4.6 mm, 3.5 &#x003bc;m) by isocratic or in gradient elution. A concentrated stock solution of standards was prepared dissolving in acetonitrile an exactly weighted amount of the standards in a 5 mL volumetric flask; serial dilutions were performed obtaining solutions used to construct the calibration curves. A volume of 5 &#x000b5;L of each solution was injected. Peak area of each compounds was plotted vs. actual concentrations (mg/mL). Linearity was assessed through evaluation of the coefficient of determination (R<sup>2</sup>). Method details for each standard are reported below:<list list-type="simple"><list-item><label>&#x02212;</label><p>Furanodienone (compound <bold>1</bold>): flow 0.5 mL/min, temperature 30 &#x000b0;C; gradient elution: 0&#x02013;10 min (50% acetonitrile), 10&#x02013;40 min (100% acetonitrile), 222 nm, tR = 14.10 min.</p></list-item><list-item><label>&#x02212;</label><p>Furanoeudesma-1,3-diene (compound <bold>2</bold>): flow 0.5 mL/min, temperature 30 &#x000b0;C; gradient elution: 0&#x02013;15 min (80% acetonitrile), 15&#x02013;30 min (100% acetonitrile), 222 nm, tR = 13.00 min.</p></list-item><list-item><label>&#x02212;</label><p>Curzerene (compound <bold>3</bold>): flow 0.5 mL/min, 18 &#x000b0;C, isocratic elution acetonitrile 70/water 30, 222 nm, tR = 30.02 min.</p></list-item><list-item><label>&#x02212;</label><p>&#x003b2;-elemene (compound <bold>4</bold>): flow 1 mL/min, 18 &#x000b0;C, isocratic elution acetonitrile 80/water 20, 205 nm, tR = 17.65 min.</p></list-item></list></p><p>An exactly weighted amount of myrrh extract was solubilized in acetonitrile (concentration ranging from 4 to 8 mg/mL) and 5 &#x000b5;L of this solution was injected for each HPLC analysis.</p></sec><sec id="sec3dot4-pharmaceuticals-14-00243"><title>3.4. Analysis Gas-Chromatography&#x02013;Mass Spectrometry (GC&#x02013;MS) Analysis</title><p>The analysis of <italic>C. myhrra</italic> oil was carried out by a gas chromatograph equipped with flame ionization detector (FID) and a split&#x02013;splitless injector and directly coupled to a mass spectrometer (MS) Perkin Elmer Clarus 500 model (Waltham, MA, USA). A Varian FactorFour VF-1 fused-silica capillary column (length 60 m &#x000d7; 0.32 mm ID &#x000d7; 1.0 &#x003bc;m film thickness) was used with helium as carrier gas (1.0 mL/min). A volume of 1 &#x003bc;L of EO oil was diluted in 1 mL of acetonitrile and the injection volume was 1&#x003bc;L. The chromatograph was equipped with a split/split less injector used in the split-less mode. The oven GC temperature program was as follows: from 70 to 250 &#x000b0;C at a rate of 5 &#x000b0;C/min, and held for 10 min; the injector temperature was 280 &#x000b0;C.</p><p>The electron-impact ionization mass spectrometer was operated as follows: ionization voltage, 70 eV; ion source temperature, 200 &#x000b0;C; scan mode, 40.0&#x02013;450.0 mass range. GC&#x02013;FID analyses were performed under the same operative conditions as described for the GC&#x02013;MS measurements. The FID temperature was 280 &#x000b0;C. The identification of the components was assigned by matching their mass spectra with that reported on MS library search (Wiley and Nist). Furthermore, linear retention indices (LRIs) were calculated using a mixture of aliphatic hydrocarbons (<italic>n</italic>-alkanes C8-C30, Ultrasci) injected directly into GC injector at the same temperature program described above and compared with those reported in reference libraries. Two components were also identified by co-injection with an authentic sample. The semi-quantitative analysis was performed by normalizing the peak area generated in FID (%) without using corrections factors (RRFs). The analysis was repeated three times.</p></sec><sec id="sec3dot5-pharmaceuticals-14-00243"><title>3.5. Cell Cultures and Viral Production</title><p>A549 (ATCC catalogue no. CCL-185), and MDCK (ATCC catalogue no. CCL-34) were used to determine the antiviral activity of myrrh oil and its metabolites. Cell lines were maintained in high glucose Dulbecco&#x02019;s Modified Eagle&#x02019;s Medium with sodium pyruvate and L-glutamine (DMEM; Euroclone, Milan, Italy), Minimum Essential Medium Eagle (EMEM; Euroclone, Milan, Italy) or Roswell Park Memorial Institute medium (RPMI-1640, Sigma, Milan, Italy) supplemented with 10% Fetal Bovine Serum (FBS; Euroclone, Milan, Italy) and 1% Penicillin/Streptomycin (Pen/Strep, Euroclone, Milan, Italy).</p><p>Allantoic cavities of 11-day-old embryonated chicken eggs were used to growth influenza virus A/Puerto Rico/8/34 H1N1 (PR8 virus). Viral suspension was inoculated in the allantoic cavity and incubated for 48 h at 37 &#x000b0;C, then infected eggs were maintained overnight at 4 &#x000b0;C. Subsequently, the allantoic fluid was collected and clarified by centrifugation (2500&#x000d7; <italic>g</italic> for 30 min). The recovered virus was used for the infection of MDCK and A549 cells. Allantoic fluid from uninfected eggs was used as reference for mock infection.</p></sec><sec id="sec3dot6-pharmaceuticals-14-00243"><title>3.6. Cytotoxicity Assay</title><p>The cytotoxicity assay was evaluated on cell lines used for influenza virus infection by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. Briefly, cells were seeded in 96-well plates at a density of 2 &#x000d7; 10<sup>4</sup> cells/well in 100 &#x003bc;L of complete RPMI medium without phenol red for 24 h at 37 &#x000b0;C. Subsequently, cell monolayers were treated or not with increasing concentrations (2.5&#x02013;500 &#x003bc;g/mL) of compounds for 24 h at 37 &#x000b0;C. After 24 h, 10 &#x003bc;L of MTT solution (5 mg/mL) was added to each well for 4 h at 37 &#x000b0;C. Afterwards, each sample was acidified by adding 0.1 N HCl in isopropanol (100 &#x003bc;L/well) for 30 min in slow agitation to ensure that all formazan crystals were dissolved. Absorbance of samples was read at 570 nm, using an automatic plate reader (Multiskan EX, Ascent Software, Thermo Fisher Scientific, Milan, Italy). Untreated cells were used as control.</p></sec><sec id="sec3dot7-pharmaceuticals-14-00243"><title>3.7. Hemagglutination (HAU) Assay</title><p>Virus production was evaluated in the supernatants of infected cells recovered 24 h after infection, by measuring the hemagglutinin units (HAU), using human type 0 Rh+ erythrocytes [<xref rid="B19-pharmaceuticals-14-00243" ref-type="bibr">19</xref>]. Stock solutions of compounds dissolved in DMSO were diluted in RPMI medium to final concentrations of 2.5&#x02013;500 &#x000b5;g/mL. Compounds were added after the adsorption period and maintained in the culture media until the end of the experiments. The highest DMSO concentration present in the culture medium was 0.2%. Control cells were treated with DMSO alone at the same concentration present in the test substance being evaluated.</p></sec><sec id="sec3dot8-pharmaceuticals-14-00243"><title>3.8. In Cell Western Assay</title><p>The ICW assay was performed using the Odyssey Imaging System (LI-COR, Lincoln, NE, USA) [<xref rid="B19-pharmaceuticals-14-00243" ref-type="bibr">19</xref>]. Briefly, A549 cells grown in 96-well plates (2 &#x000d7; 104 cells/well), either infected or mock-infected (Ctr) with PR8, were fixed with 4% formaldehyde, washed, permeabilized with 0.1% Triton X-100 and incubated with PBS containing Odyssey Blocking buffer (LI-COR Biosciences, Lincoln, NE, USA).</p><p>The cells were stained at 4 &#x000b0;C overnight with primary antibodies against influenza Nucleoprotein (NP) or Hemagglutinin (HA). After incubation, three washes with PBS plus 0.1% Tween 20 were performed and then the cells were stained with a mixture of fluorochrome-conjugated secondary antibodies (fluorescence emission at 800 nm), properly diluted in Odyssey blocking buffer and fluorochrome-conjugated Cell Tag (fluorescence emission at 700 nm), for 1 h at room temperature. Cell Tag was used as control of the integrity of cell monolayer. Subsequently, three washes with PBS plus 0.1% Tween 20 were performed and plates were analyzed by the Odyssey infrared imaging system (LI-COR). Integrated intensities of fluorescence were determined by the LI-COR Image Studio software and the relative fluorescence intensity (RFI) was expressed as percentage compared to untreated infected cells (100%).</p></sec><sec id="sec3dot9-pharmaceuticals-14-00243"><title>3.9. Time-of-Addition Assay</title><p>A549 cells were seeded in 12-well plates at a density of 2.5 &#x000d7; 10<sup>5</sup> cells/mL for 24 h at 37 &#x000b0;C, infected with PR8 and treated or not with furanodienone (<bold>1</bold>) or curzerene (<bold>3</bold>) (80 &#x003bc;g/mL) at different phases of the virus lifecycle, as indicated in the Results section. Untreated infected cells were used as control. Cell supernatants were recovered to infect fresh monolayer and to analyze viral protein expression by ICW assay. Statistical significance of the data was analyzed by means of a Student <italic>t</italic> test and <italic>p</italic> values &#x0003c; 0.05 were considered significant. Data were expressed as mean &#x000b1; the standard deviation (SD).</p></sec></sec><sec sec-type="conclusions" id="sec4-pharmaceuticals-14-00243"><title>4. Conclusions</title><p>In conclusion, we reported the extraction of <italic>C. myrrha</italic> by supercritical CO<sub>2</sub>, an extraction method that allowed avoiding undesired chemical reactions during the process. In addition, the analysis of the obtained myrrh oil and the quantification of its metabolites were performed by HPLC, so as to avoid high temperatures also during the analytical process. Interestingly, our study demonstrated that myrrh oil shows antiviral activity against influenza A Puerto Rico 8/34/H1N1 virus. Due the toxicity exerted by myrrh oil alone on the cell lines used for viral infection, we decided to add Vit. E acetate (1% <italic>w</italic>/<italic>v</italic>) that led to an increase in the viability of cells treated with the extract. It was also possible to appreciate the antiviral activity of myrrh oil plus Vit. E acetate. In particular, in the hemagglutination assay, the mixture of myrrh oil and the antioxidant compound showed a reduction in viral replication in a dose-dependent manner. Moreover, the expression of viral nucleoprotein was reduced using myrrh oil at 25 and 50 &#x000b5;g/mL in mixture with Vit. E acetate. Lastly, to investigate the antiviral activity of the main myrrh oil components, the single sesquiterpenes commercially available were tested. At non-toxic concentrations, the most active compounds, curzerene and furanodienone, proved to be effective at different steps of the virus lifecycle: furanodienone was mainly effective before and immediately after infection while curzerene was mainly active during viral adsorption. According to our results, myrrh and its metabolites may be useful to develop new antiviral agents active against influenza virus.</p></sec></body><back><ack><title>Acknowledgments</title><p>We wish to thank the Exenia Group (Pinerolo, TO, Italy) for providing the SCFE extracts.</p></ack><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, D.D.V., L.S., R.C., R.D.S. and L.N.; methodology, V.N.M., D.D.V., M.D.A., S.G. and G.D.C.; validation, A.M., A.D.L., V.T., D.I., M.D.A. and G.D.C.; formal analysis, M.D.A. and G.D.C.; investigation, D.D.V., V.N.M., A.M., A.D.L., V.T., D.I., M.D.A., S.G. and G.D.C.; resources and project administration, L.S., R.C., R.D.S. and L.N.; writing&#x02014;original draft preparation, V.N.M., D.D.V., and L.N.; writing&#x02014;review and editing, V.N.M., D.D.V., A.M., F.S., S.G., R.C. and L.N.; visualization, V.N.M., D.D.V., and L.N.; supervision, D.D.V., L.S., R.C., R.D.S., A.T.P. and L.N.; funding acquisition, R.C., A.T.P. and L.N. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research was funded by MIUR-PRIN 2017, 2017BMK8JR006 (project &#x0201c;ORIGINALE CHEMIAE in Antiviral Strategy&#x02014;Origin and Modernization of Multi-Component Chemistry as a Source of Innovative Broad Spectrum Antiviral Strategy&#x0201d;) (LN), MIUR-PONARS 01_00597_OR4 (ATP) grants.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available on request from the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceuticals-14-00243"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suleiman</surname><given-names>M.H.A.</given-names></name></person-group><article-title>Prenylated flavonoids from the stem wood of <italic>Commiphora opobalsamum</italic> (L.) Engl.(Burseraceae)</article-title><source>J. King Saud Univ. Sci.</source><year>2015</year><volume>27</volume><fpage>71</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.jksus.2014.04.005</pub-id></element-citation></ref><ref id="B2-pharmaceuticals-14-00243"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latha</surname><given-names>S.</given-names></name><name><surname>Selvamani</surname><given-names>P.</given-names></name><name><surname>Prabha</surname><given-names>T.</given-names></name></person-group><article-title>Pharmacological uses of the plants belonging to the genus Commiphora</article-title><source>Cardiovasc. Hematol. Agents Med. Chem.</source><year>2020</year><pub-id pub-id-type="doi">10.2174/1871525718666200702125558</pub-id><?supplied-pmid 32614755?><pub-id pub-id-type="pmid">32614755</pub-id></element-citation></ref><ref id="B3-pharmaceuticals-14-00243"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanu&#x00161;</surname><given-names>L.O.</given-names></name><name><surname>R&#x0011b;zanka</surname><given-names>T.</given-names></name><name><surname>Dembitsky</surname><given-names>V.M.</given-names></name><name><surname>Moussaieff</surname><given-names>A.</given-names></name></person-group><article-title>Myrrh-Commiphora chemistry</article-title><source>Biomed. Pap.</source><year>2005</year><volume>149</volume><fpage>3</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.5507/bp.2005.001</pub-id><?supplied-pmid 16170385?><pub-id pub-id-type="pmid">16170385</pub-id></element-citation></ref><ref id="B4-pharmaceuticals-14-00243"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morteza-Semnani</surname><given-names>K.</given-names></name><name><surname>Saeedi</surname><given-names>M.</given-names></name></person-group><article-title>Constituents of the essential oil of <italic>Commiphora myrrha</italic> (Nees) Engl. var. <italic>molmol</italic></article-title><source>J. Essent. Oil Res.</source><year>2003</year><volume>15</volume><fpage>50</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1080/10412905.2003.9712264</pub-id></element-citation></ref><ref id="B5-pharmaceuticals-14-00243"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shalaby</surname><given-names>M.A.</given-names></name><name><surname>Hammouda</surname><given-names>A.A.</given-names></name></person-group><article-title>Analgesic, anti-inflammatory and anti-hyperlipidemic activities of <italic>Commiphora molmol</italic> extract (Myrrh)</article-title><source>J. Intercult. Ethnopharmacol.</source><year>2014</year><volume>3</volume><fpage>56</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.5455/jice.20140130015014</pub-id><?supplied-pmid 26401348?><pub-id pub-id-type="pmid">26401348</pub-id></element-citation></ref><ref id="B6-pharmaceuticals-14-00243"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>C.</given-names></name><name><surname>Ge</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Feng</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Wei</surname><given-names>T.</given-names></name></person-group><article-title>Composition and potential anticancer activities of essential oils obtained from myrrh and frankincense</article-title><source>Oncol. Lett.</source><year>2013</year><volume>6</volume><fpage>1140</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.3892/ol.2013.1520</pub-id><?supplied-pmid 24137478?><pub-id pub-id-type="pmid">24137478</pub-id></element-citation></ref><ref id="B7-pharmaceuticals-14-00243"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Molecular targets of &#x003b2;-elemene, a herbal extract used in traditional Chinese medicine, and its potential role in cancer therapy: A review</article-title><source>Biomed. Pharmacother.</source><year>2019</year><volume>114</volume><fpage>108812</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2019.108812</pub-id><?supplied-pmid 30965237?><pub-id pub-id-type="pmid">30965237</pub-id></element-citation></ref><ref id="B8-pharmaceuticals-14-00243"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Messina</surname><given-names>F.</given-names></name><name><surname>Gigliarelli</surname><given-names>G.</given-names></name><name><surname>Palmier</surname><given-names>A.</given-names></name><name><surname>Marcotullio</surname><given-names>M.C.</given-names></name></person-group><article-title>Furanodienone: An emerging bioactive furanosesquiterpenoid</article-title><source>Curr. Org. Chem.</source><year>2017</year><volume>21</volume><fpage>305</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.2174/1385272820666161018130431</pub-id></element-citation></ref><ref id="B9-pharmaceuticals-14-00243"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N.</given-names></name><name><surname>Kikuzaki</surname><given-names>H.</given-names></name><name><surname>Sheng</surname><given-names>S.</given-names></name><name><surname>Sang</surname><given-names>S.</given-names></name><name><surname>Rafi</surname><given-names>M.M.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Nakatani</surname><given-names>N.</given-names></name><name><surname>Di Paola</surname><given-names>R.S.</given-names></name><name><surname>Rosen</surname><given-names>R.T.</given-names></name><name><surname>Ho</surname><given-names>C.-T.</given-names></name></person-group><article-title>Furanosesquiterpenoids of <italic>Commiphora myrrha</italic></article-title><source>J. Nat. Prod.</source><year>2001</year><volume>64</volume><fpage>1460</fpage><lpage>1462</lpage><pub-id pub-id-type="doi">10.1021/np010072j</pub-id><?supplied-pmid 11720534?><pub-id pub-id-type="pmid">11720534</pub-id></element-citation></ref><ref id="B10-pharmaceuticals-14-00243"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Ashry</surname><given-names>E.S.H.</given-names></name><name><surname>Rashed</surname><given-names>N.</given-names></name><name><surname>Salama</surname><given-names>O.M.</given-names></name><name><surname>Saleh</surname><given-names>A.</given-names></name></person-group><article-title>Components, therapeutic value and uses of myrrh</article-title><source>Pharmazie</source><year>2003</year><volume>58</volume><fpage>163</fpage><lpage>168</lpage><?supplied-pmid 12685809?><pub-id pub-id-type="pmid">12685809</pub-id></element-citation></ref><ref id="B11-pharmaceuticals-14-00243"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>R.</given-names></name><name><surname>de Morais</surname><given-names>S.A.L.</given-names></name><name><surname>Napolitano</surname><given-names>D.R.</given-names></name><name><surname>Duarte</surname><given-names>K.C.</given-names></name><name><surname>Guzman</surname><given-names>V.B.</given-names></name><name><surname>Nascimento</surname><given-names>E.A.</given-names></name></person-group><article-title>A new approach for quantifying furanodiene and curzerene: A case study on the essential oils of <italic>Eugenia uniflora L.</italic>, Myrtaceae (pitangueira) leaves</article-title><source>Rev. Bras. Farmacogn.</source><year>2011</year><volume>21</volume><fpage>392</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1590/S0102-695X2011005000042</pub-id></element-citation></ref><ref id="B12-pharmaceuticals-14-00243"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marongiu</surname><given-names>B.</given-names></name><name><surname>Piras</surname><given-names>A.</given-names></name><name><surname>Porcedda</surname><given-names>S.</given-names></name><name><surname>Scorciapino</surname><given-names>A.</given-names></name></person-group><article-title>Chemical composition of the essential oil and supercritical CO<sub>2</sub> extract of <italic>Commiphora myrrha</italic> (Nees) Engl. and of <italic>Acorus calamus</italic> L.</article-title><source>J. Agric. Food Chem.</source><year>2005</year><volume>53</volume><fpage>7939</fpage><lpage>7943</lpage><pub-id pub-id-type="doi">10.1021/jf051100x</pub-id><?supplied-pmid 16190653?><pub-id pub-id-type="pmid">16190653</pub-id></element-citation></ref><ref id="B13-pharmaceuticals-14-00243"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pescatori</surname><given-names>L.</given-names></name><name><surname>Metifiot</surname><given-names>M.</given-names></name><name><surname>Chung</surname><given-names>S.</given-names></name><name><surname>Masoaka</surname><given-names>T.</given-names></name><name><surname>Cuzzucoli Crucitti</surname><given-names>G.</given-names></name><name><surname>Messore</surname><given-names>A.</given-names></name><name><surname>Pupo</surname><given-names>G.</given-names></name><name><surname>Madia</surname><given-names>V.N.</given-names></name><name><surname>Saccoliti</surname><given-names>F.</given-names></name><name><surname>Scipione</surname><given-names>L.</given-names></name><etal/></person-group><article-title><italic>N</italic>-Substituted quinolinonyl diketo acid derivatives as HIV integrase strand transfer inhibitors and their activity against RNase H function of reverse transcriptase</article-title><source>J. Med. Chem.</source><year>2015</year><volume>58</volume><fpage>4610</fpage><lpage>4623</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b00159</pub-id><?supplied-pmid 25961960?><pub-id pub-id-type="pmid">25961960</pub-id></element-citation></ref><ref id="B14-pharmaceuticals-14-00243"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costi</surname><given-names>R.</given-names></name><name><surname>Di Santo</surname><given-names>R.</given-names></name><name><surname>Artico</surname><given-names>M.</given-names></name><name><surname>Miele</surname><given-names>G.</given-names></name><name><surname>Valentini</surname><given-names>P.</given-names></name><name><surname>Novellino</surname><given-names>E.</given-names></name><name><surname>Cereseto</surname><given-names>A.</given-names></name></person-group><article-title>Cinnamoyl compounds as simple molecules that inhibit p300 histone acetyltransferase</article-title><source>J. Med. Chem.</source><year>2007</year><volume>50</volume><fpage>1973</fpage><lpage>1977</lpage><pub-id pub-id-type="doi">10.1021/jm060943s</pub-id><?supplied-pmid 17348637?><pub-id pub-id-type="pmid">17348637</pub-id></element-citation></ref><ref id="B15-pharmaceuticals-14-00243"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bizzarri</surname><given-names>B.M.</given-names></name><name><surname>Fanelli</surname><given-names>A.</given-names></name><name><surname>Piccinino</surname><given-names>D.</given-names></name><name><surname>De Angelis</surname><given-names>M.</given-names></name><name><surname>Dolfa</surname><given-names>C.</given-names></name><name><surname>Palamara</surname><given-names>A.T.</given-names></name><name><surname>Nencioni</surname><given-names>L.</given-names></name><name><surname>Zippilli</surname><given-names>C.</given-names></name><name><surname>Crucianelli</surname><given-names>M.</given-names></name><name><surname>Saladino</surname><given-names>R.</given-names></name></person-group><article-title>Synthesis of stilbene and chalcone inhibitors of influenza A virus by SBA-15 supported Hoveyda-Grubbs metathesis</article-title><source>Catalysts</source><year>2019</year><volume>9</volume><elocation-id>983</elocation-id><pub-id pub-id-type="doi">10.3390/catal9120983</pub-id></element-citation></ref><ref id="B16-pharmaceuticals-14-00243"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>S.C.</given-names></name><name><surname>Mathela</surname><given-names>C.S.</given-names></name></person-group><article-title>Antioxidant and antibacterial activities of the leaf essential oil and its constituents furanodienone and curzerenone from <italic>Lindera pulcherrima</italic> (Nees.) Benth. ex hook. f</article-title><source>Pharmacogn. Res.</source><year>2012</year><volume>4</volume><fpage>80</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.4103/0974-8490.94721</pub-id></element-citation></ref><ref id="B17-pharmaceuticals-14-00243"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celestino</surname><given-names>I.</given-names></name><name><surname>Checconi</surname><given-names>P.</given-names></name><name><surname>Amatore</surname><given-names>D.</given-names></name><name><surname>De Angelis</surname><given-names>M.</given-names></name><name><surname>Coluccio</surname><given-names>P.</given-names></name><name><surname>Dattilo</surname><given-names>R.</given-names></name><name><surname>Alunni Fegatelli</surname><given-names>D.</given-names></name><name><surname>Clemente</surname><given-names>A.M.</given-names></name><name><surname>Matarrese</surname><given-names>P.</given-names></name><name><surname>Torcia</surname><given-names>M.G.</given-names></name><etal/></person-group><article-title>Differential redox state contributes to sex disparities in the response to influenza virus infection in male and female mice</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>1747</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01747</pub-id><?supplied-pmid 30105026?><pub-id pub-id-type="pmid">30105026</pub-id></element-citation></ref><ref id="B18-pharmaceuticals-14-00243"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Sotto</surname><given-names>A.</given-names></name><name><surname>Checconi</surname><given-names>P.</given-names></name><name><surname>Celestino</surname><given-names>I.</given-names></name><name><surname>Locatelli</surname><given-names>M.</given-names></name><name><surname>Carissimi</surname><given-names>S.</given-names></name><name><surname>De Angelis</surname><given-names>M.</given-names></name><name><surname>Rossi</surname><given-names>V.</given-names></name><name><surname>Limongi</surname><given-names>D.</given-names></name><name><surname>Toniolo</surname><given-names>C.</given-names></name><name><surname>Martinoli</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Antiviral and antioxidant activity of a hydroalcoholic extract from <italic>Humulus lupulus</italic> L.</article-title><source>Oxidat. Med. Cell. Long.</source><year>2018</year><volume>2018</volume><fpage>e5919237</fpage><pub-id pub-id-type="doi">10.1155/2018/5919237</pub-id><?supplied-pmid 30140367?><pub-id pub-id-type="pmid">30140367</pub-id></element-citation></ref><ref id="B19-pharmaceuticals-14-00243"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fioravanti</surname><given-names>R.</given-names></name><name><surname>Celestino</surname><given-names>I.</given-names></name><name><surname>Costi</surname><given-names>R.</given-names></name><name><surname>Cuzzucoli Crucitti</surname><given-names>G.</given-names></name><name><surname>Pescatori</surname><given-names>L.</given-names></name><name><surname>Mattiello</surname><given-names>L.</given-names></name><name><surname>Novellino</surname><given-names>E.</given-names></name><name><surname>Checconi</surname><given-names>P.</given-names></name><name><surname>Palamara</surname><given-names>A.T.</given-names></name><name><surname>Nencioni</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Effects of polyphenol compounds on influenza A virus replication and definition of their mechanism of action</article-title><source>Bioorg. Med. Chem.</source><year>2012</year><volume>20</volume><fpage>5046</fpage><lpage>5052</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2012.05.062</pub-id><?supplied-pmid 22743086?><pub-id pub-id-type="pmid">22743086</pub-id></element-citation></ref><ref id="B20-pharmaceuticals-14-00243"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Vita</surname><given-names>D.</given-names></name><name><surname>Messore</surname><given-names>A.</given-names></name><name><surname>Toniolo</surname><given-names>C.</given-names></name><name><surname>Frezza</surname><given-names>C.</given-names></name><name><surname>Scipione</surname><given-names>L.</given-names></name><name><surname>Bertea</surname><given-names>C.M.</given-names></name><name><surname>Micera</surname><given-names>M.</given-names></name><name><surname>Di Sarno</surname><given-names>V.</given-names></name><name><surname>Madia</surname><given-names>V.N.</given-names></name><name><surname>Pindinello</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Towards a new application of amaranth seed oil as an agent against <italic>Candida albicans</italic></article-title><source>Nat. Prod. Res.</source><year>2019</year><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1080/14786419.2019.1696335</pub-id><?supplied-pmid 31795749?><pub-id pub-id-type="pmid">31795749</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="pharmaceuticals-14-00243-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Structures of the main sesquiterpenes in myrrh oil: furanodienone (<bold>1</bold>), furanoeudesma-1,3-diene (<bold>2</bold>), curzerene (<bold>3</bold>) and &#x003b2;-elemene (<bold>4</bold>).</p></caption><graphic xlink:href="pharmaceuticals-14-00243-g001"/></fig><fig id="pharmaceuticals-14-00243-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>The mixture myrrh oil and vitamin E (Vit. E) acetate increased cell viability. A549 cells were treated with different concentrations (3&#x02013;100 &#x000b5;g/mL) myrrh oil, Vit. E acetate (0.03&#x02013;1 &#x000b5;g/mL) and a mixture of myrrh oil (3&#x02013;100 &#x000b5;g/mL) with Vit. E acetate (0.03&#x02013;1 &#x000b5;g/mL). Cells treated with DMSO were used as control. After 24 h, cell monolayers were fixed and stained with Cell Tag. The effect of compounds on the integrity of cell monolayers was analyzed by In-Cell Western assay (ICW), using LI-COR Image Studio Software. Images are representative of one experiment of two replicates, each performed in duplicate. The graph indicates the percentage of relative fluorescence intensity (RFI) of Cell Tag expressed on myrrh oil and myrrh oil + Vit. E acetate compared to Vit. E acetate is considered as 100%. Values are the mean &#x000b1; S.D. of two replicates of one experiment performed in duplicate (<italic>n</italic> = 2); ** <italic>p</italic> &#x0003c; 0.01 vs. Vit. E acetate.</p></caption><graphic xlink:href="pharmaceuticals-14-00243-g002"/></fig><fig id="pharmaceuticals-14-00243-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>The mixture myrrh oil and Vit. E acetate inhibits influenza A virus replication. A549 cells were infected with PR8 and, after viral adsorption, treated with different concentrations myrrh oil (25, 50 and 100 &#x000b5;g/mL), Vit. E acetate (0.25&#x02013;1 &#x000b5;g/mL) and myrrh oil (25, 50 and 100 &#x000b5;g/mL) in mixture with Vit. E acetate (0.25&#x02013;1 &#x000b5;g/mL). Cells infected with PR8 and treated with DMSO were used as control. After 24 h, cell monolayers were fixed and the expression of viral nucleoprotein (NP) was analyzed by ICW, using LI-COR Image Studio Software. Images are representative of one experiment of two replicates, each performed in duplicate.</p></caption><graphic xlink:href="pharmaceuticals-14-00243-g003"/></fig><fig id="pharmaceuticals-14-00243-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Compounds 1 and 3 affect different steps of virus lifecycle. A549 cells were infected with PR8 and treated or not with furanodienone (<bold>1</bold>) or curzerene (<bold>3</bold>) at different phases of the virus life cycle: the compounds were added for 2 h before (PRE); during viral adsorption for 1 h (DUR); immediately after viral adsorption and maintained for 24 h (POST). After 24 h infection, supernatants were recovered and used to infect a fresh monolayer of MDCK cells. The expression of viral Hemagglutinin (HA) was analyzed by ICW assay, using LI-COR Image Studio Software, as described in Methods. The percentage of RFI was calculated in comparison to Infected (I) cells (considered 100%). Values are the mean &#x000b1; S.D. of three replicates (<italic>n</italic> = 3) of one out two experiments performed. Statistical significance of the data vs. I was defined as * <italic>p</italic> &#x0003c; 0.01 and ** <italic>p</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="pharmaceuticals-14-00243-g004"/></fig><table-wrap id="pharmaceuticals-14-00243-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-14-00243-t001_Table 1</object-id><label>Table 1</label><caption><p>Percentage of compounds analyzed in the oil of <italic>C. myrrha</italic> extracted by supercritical fluid extraction (SCFE)-CO<sub>2</sub> technique.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">% (<italic>w</italic>/<italic>w</italic>)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">LOQ</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">LOD</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">nd <sup>1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">3.62</td><td align="center" valign="middle" rowspan="1" colspan="1">1.19</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>2</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">10.48</td><td align="center" valign="middle" rowspan="1" colspan="1">1.61</td><td align="center" valign="middle" rowspan="1" colspan="1">0.53</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>3</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.35</td><td align="center" valign="middle" rowspan="1" colspan="1">3.81</td><td align="center" valign="middle" rowspan="1" colspan="1">1.26</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>4</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.59</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.86</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Not detected; LOQ = limit of quantification (&#x000b5;g/mL): 10 &#x000d7; (SE/S); LOD = limit of detection (&#x000b5;g/mL): 3.3 &#x000d7; (SE/S); SE = standard deviation of regression of y intercept; S: slope of the linear calibration line.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pharmaceuticals-14-00243-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-14-00243-t002_Table 2</object-id><label>Table 2</label><caption><p>Chemical volatile composition (%) of myrrh oil.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N&#x000b0;</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">COMPONENT <sup>1</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">LRI <sup>2</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">LRI <sup>3</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MS <sup>4</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">(%) <sup>5</sup></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b4;-elemene</td><td align="center" valign="middle" rowspan="1" colspan="1">1345</td><td align="center" valign="middle" rowspan="1" colspan="1">1347</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">copaene</td><td align="center" valign="middle" rowspan="1" colspan="1">1377</td><td align="center" valign="middle" rowspan="1" colspan="1">1379</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b2;-elemene</td><td align="center" valign="middle" rowspan="1" colspan="1">1381</td><td align="center" valign="middle" rowspan="1" colspan="1">1387</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b3;-elemene</td><td align="center" valign="middle" rowspan="1" colspan="1">1443</td><td align="center" valign="middle" rowspan="1" colspan="1">1445</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">2.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">humulene</td><td align="center" valign="middle" rowspan="1" colspan="1">1470</td><td align="center" valign="middle" rowspan="1" colspan="1">1473</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">curzerene</td><td align="center" valign="middle" rowspan="1" colspan="1">1491</td><td align="center" valign="middle" rowspan="1" colspan="1">1495</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">23.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">germacrene D</td><td align="center" valign="middle" rowspan="1" colspan="1">1498</td><td align="center" valign="middle" rowspan="1" colspan="1">1500</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b4;-guajene</td><td align="center" valign="middle" rowspan="1" colspan="1">1501</td><td align="center" valign="middle" rowspan="1" colspan="1">1508</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b4;-cadinene</td><td align="center" valign="middle" rowspan="1" colspan="1">1505</td><td align="center" valign="middle" rowspan="1" colspan="1">1509</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b3;-cadinene</td><td align="center" valign="middle" rowspan="1" colspan="1">1533</td><td align="center" valign="middle" rowspan="1" colspan="1">1536</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">elemol</td><td align="center" valign="middle" rowspan="1" colspan="1">1539</td><td align="center" valign="middle" rowspan="1" colspan="1">1543</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">caryophyllene oxide</td><td align="center" valign="middle" rowspan="1" colspan="1">1585</td><td align="center" valign="middle" rowspan="1" colspan="1">1583</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">spathulenol</td><td align="center" valign="middle" rowspan="1" colspan="1">1603</td><td align="center" valign="middle" rowspan="1" colspan="1">1601</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b3;-eudesmol</td><td align="center" valign="middle" rowspan="1" colspan="1">1631</td><td align="center" valign="middle" rowspan="1" colspan="1">1630</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">isoserecenin</td><td align="center" valign="middle" rowspan="1" colspan="1">1790</td><td align="center" valign="middle" rowspan="1" colspan="1">1799 *</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">furanodienone</td><td align="center" valign="middle" rowspan="1" colspan="1">1870</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000a7;</td><td align="center" valign="middle" rowspan="1" colspan="1">+ <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">1.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">furanoeudesma-1,3-dione</td><td align="center" valign="middle" rowspan="1" colspan="1">2155</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000a7;</td><td align="center" valign="middle" rowspan="1" colspan="1">+ <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">31.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">lindestrene</td><td align="center" valign="middle" rowspan="1" colspan="1">2162</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000a7;</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">11.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">germacra-1(10),7,11-trien-15-oic acid, 8,12-epoxy-6-hydroxy-gamma-lactone</td><td align="center" valign="middle" rowspan="1" colspan="1">2170</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000a7;</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">14.4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">1-(2,4-diemthylphenyl)-2-(2-furyl) cyclopropane</td><td align="center" valign="middle" rowspan="1" colspan="1">2180</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000a7;</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">2.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">21</td><td align="center" valign="middle" rowspan="1" colspan="1">cycloisolongifolene, 8,9-dehydro-9-formyl-</td><td align="center" valign="middle" rowspan="1" colspan="1">2200</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000a7;</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">2.4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">8-hydroxy-3,8a-dimethyl-5-methylene-2-oxododecahydronaphto[2,3-b]furan-4-yl acetate</td><td align="center" valign="middle" rowspan="1" colspan="1">2210</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x000a7;</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TOTAL (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.9</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> The components are reported according their elution order on an apolar column; <sup>2</sup> linear retention indices measured on an apolar column; <sup>3</sup> linear retention indices from the literature; &#x000a7;: linear retention indices (LRI) not available for apolar column; *: Kovats Index RI; <sup>4</sup> MS: identification by comparison of the mass spectra with those present in the libraries; <sup>a</sup>: identification confirmed by co-injection of an authentic sample; <sup>5</sup> percentage mean values of <italic>C. myrrha</italic> oil components (%).</p></fn></table-wrap-foot></table-wrap><table-wrap id="pharmaceuticals-14-00243-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-14-00243-t003_Table 3</object-id><label>Table 3</label><caption><p>Antiviral activity of <italic>C. myrrha</italic> SCFE-CO<sub>2</sub> extract alone and in combination with Vit. E acetate.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="7" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Viral Titer (HAU/mL) <sup>1</sup></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Myrrh oil</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5 <sup>2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Myrrh oil + Vit. E acetate (1% <italic>w</italic>/<italic>v</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DMSO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Myrrh oil concentration (&#x003bc;g/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Viral titer was measured by hemagglutination assay (HAU/mL) in the supernatant of infected cells treated or not with the compounds alone or in combination with Vit. E (1%), DMSO was used as control. Viral titer for Vit. E acetate was equal to 8 HAU/mL at all the tested concentrations (0.03&#x02013;1 &#x003bc;g/mL); <sup>2</sup> SD &#x000b1; 0.5.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pharmaceuticals-14-00243-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-14-00243-t004_Table 4</object-id><label>Table 4</label><caption><p>Antiviral activity of <bold>1</bold> and <bold>3.</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Viral Titer (HAU/mL) <sup>1</sup></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">6 <sup>2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>3</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 <sup>3</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Concentration (&#x003bc;g/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Viral titer was measured by hemagglutination assay (HAU/mL) in the supernatant of infected cells treated or not with the compounds; <sup>2</sup> SD &#x000b1; 2; <sup>3</sup> SD &#x000b1; 01.</p></fn></table-wrap-foot></table-wrap></floats-group></article>